system_prompt: 'As an advanced medical reading comprehension assistant, your task is to analyze clinical documents, medical literature, and patient information to answer medical questions accurately. Your response starts after "Clinical Reasoning: ", where you will methodically break down the medical reasoning process, considering relevant clinical findings, patient history, and medical knowledge. Conclude with "Answer: " to present a concise, clinically accurate response.'
doc_prompt: "Medical Document: {title}\n{content}\n"
question_prompt: "Question: {question}\nClinical Reasoning: "
examples:
  - input: |-
      Medical Document: Type 2 Diabetes Mellitus - Pharmacological Management
      Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by insulin resistance and relative insulin deficiency. First-line pharmacological treatment typically involves metformin, an oral biguanide that reduces hepatic glucose production and improves insulin sensitivity. The standard initial dose is 500-850mg once or twice daily with meals, titrated up to a maximum of 2000-2550mg per day divided into 2-3 doses. Metformin has been shown to reduce HbA1c by approximately 1-2% and is associated with modest weight loss and cardiovascular benefits. Common side effects include gastrointestinal disturbances such as nausea, diarrhea, and abdominal discomfort, which can be minimized by taking with food and gradual dose escalation.

      Medical Document: Metformin - Clinical Pharmacology
      Metformin hydrochloride is the most commonly prescribed oral antidiabetic medication worldwide. It belongs to the biguanide class of medications and works primarily by decreasing hepatic glucose output and improving peripheral insulin sensitivity. Unlike sulfonylureas or insulin, metformin does not cause hypoglycemia when used as monotherapy. The medication is contraindicated in patients with severe renal impairment (eGFR <30 mL/min/1.73m²) due to risk of lactic acidosis. Extended-release formulations are available and may improve gastrointestinal tolerability. The medication should be held prior to procedures involving iodinated contrast media and resumed 48 hours post-procedure if renal function is stable.

      Medical Document: Acute Myocardial Infarction - Emergency Management
      Acute myocardial infarction (AMI) is a life-threatening condition requiring immediate intervention. ST-elevation myocardial infarction (STEMI) is characterized by complete coronary artery occlusion and presents with ST-segment elevation on electrocardiogram. Immediate treatment includes aspirin 162-325mg chewed, sublingual nitroglycerin for chest pain relief, and morphine for pain control. Dual antiplatelet therapy with aspirin and a P2Y12 inhibitor (clopidogrel, ticagrelor, or prasugrel) is essential. Primary percutaneous coronary intervention (PCI) should be performed within 90 minutes of first medical contact when available. If PCI is not available within 120 minutes, fibrinolytic therapy should be considered in eligible patients presenting within 12 hours of symptom onset.

      Medical Document: Antiplatelet Therapy in Cardiovascular Disease
      Aspirin (acetylsalicylic acid) is a cornerstone of antiplatelet therapy in cardiovascular disease. It irreversibly inhibits cyclooxygenase-1 (COX-1) in platelets, thereby preventing thromboxane A2 synthesis and platelet aggregation. In acute coronary syndromes, an initial loading dose of 162-325mg (non-enteric coated, chewed) is recommended, followed by a maintenance dose of 81mg daily. The rapid onset of action makes aspirin a critical first-line intervention in suspected myocardial infarction. Common adverse effects include gastrointestinal bleeding and peptic ulcer disease, particularly at higher doses. Aspirin is contraindicated in patients with active bleeding disorders or severe aspirin allergy.

      Medical Document: Clopidogrel - P2Y12 Inhibitor
      Clopidogrel is a thienopyridine P2Y12 inhibitor used in combination with aspirin as dual antiplatelet therapy (DAPT) following acute coronary syndromes or percutaneous coronary intervention. The loading dose is 300-600mg followed by 75mg daily maintenance. Clopidogrel is a prodrug requiring hepatic conversion by CYP2C19 to its active metabolite. Patients with loss-of-function CYP2C19 polymorphisms may have reduced therapeutic response. Duration of DAPT typically ranges from 6-12 months post-PCI with drug-eluting stents, though this may be extended based on ischemic versus bleeding risk assessment. The medication increases bleeding risk and should be discontinued 5-7 days prior to elective surgery.

      Question: What is the recommended loading dose of aspirin and clopidogrel for a patient presenting with acute STEMI who will undergo primary percutaneous coronary intervention?
      Clinical Reasoning:
    response: |-
      For acute STEMI managed with primary PCI, dual antiplatelet therapy is essential. According to the emergency management guidelines, aspirin should be given as a loading dose of 162-325mg (non-enteric coated, chewed) for rapid onset. The antiplatelet therapy document confirms this loading dose followed by 81mg daily maintenance. For clopidogrel, the P2Y12 inhibitor document specifies a loading dose of 300-600mg followed by 75mg daily maintenance. Both agents work synergistically to prevent acute stent thrombosis and recurrent ischemic events.
      Answer: Aspirin 162-325mg (chewed) and Clopidogrel 300-600mg loading doses.

  - input: |-
      Medical Document: Hypertension - Definition and Classification
      Hypertension is defined as persistently elevated blood pressure ≥130/80 mmHg based on the 2017 ACC/AHA guidelines. Stage 1 hypertension is classified as systolic BP 130-139 mmHg or diastolic BP 80-89 mmHg. Stage 2 hypertension is systolic BP ≥140 mmHg or diastolic BP ≥90 mmHg. Hypertensive crisis includes hypertensive urgency (BP >180/120 mmHg without end-organ damage) and hypertensive emergency (BP >180/120 mmHg with acute end-organ damage such as encephalopathy, acute kidney injury, or myocardial infarction). Blood pressure should be measured after 5 minutes of rest using proper technique with appropriate cuff size.

      Medical Document: ACE Inhibitors - Mechanism and Clinical Use
      Angiotensin-converting enzyme (ACE) inhibitors are first-line antihypertensive agents that block the conversion of angiotensin I to angiotensin II, leading to vasodilation and reduced aldosterone secretion. Lisinopril is a commonly prescribed ACE inhibitor with once-daily dosing. The typical starting dose is 10mg once daily, titrated to a maximum of 40mg daily based on blood pressure response. ACE inhibitors provide cardiovascular and renal protection, particularly beneficial in patients with diabetes, chronic kidney disease, or heart failure. Common side effects include dry cough (occurring in 5-20% of patients due to bradykinin accumulation), hyperkalemia, and rarely angioedema. ACE inhibitors are contraindicated in pregnancy (teratogenic) and in patients with history of angioedema.

      Medical Document: Lisinopril - Pharmacokinetics
      Lisinopril is a long-acting ACE inhibitor that does not require hepatic metabolism and is eliminated unchanged by the kidneys. Peak plasma concentrations occur within 6-8 hours after oral administration, with a half-life of approximately 12 hours, allowing for once-daily dosing. The medication begins to lower blood pressure within 1 hour, with peak effect at 6 hours and duration of action up to 24 hours. Dose adjustment is required in patients with renal impairment (eGFR <30 mL/min/1.73m²). Lisinopril can be taken with or without food. When initiating therapy, blood pressure should be monitored regularly and renal function and potassium levels should be checked within 2-4 weeks.

      Medical Document: Hypertension Management in Diabetes
      Patients with diabetes and hypertension have significantly increased cardiovascular risk and require aggressive blood pressure management with a target BP <130/80 mmHg. ACE inhibitors or angiotensin receptor blockers (ARBs) are preferred first-line agents due to their renoprotective effects, reducing albuminuria and slowing progression of diabetic nephropathy. In the HOPE trial, ramipril (an ACE inhibitor) reduced cardiovascular events by 25% and progression to overt nephropathy by 24% in diabetic patients. ACE inhibitors also reduce intraglomerular pressure by preferentially dilating the efferent arteriole. Combination therapy with a thiazide diuretic or calcium channel blocker is often required to achieve target blood pressure.

      Question: A 62-year-old patient with type 2 diabetes mellitus and newly diagnosed hypertension (BP 148/92 mmHg) is being considered for ACE inhibitor therapy. What is the standard starting dose of lisinopril, and why is this medication class particularly beneficial for this patient?
      Clinical Reasoning:
    response: |-
      This patient has type 2 diabetes with stage 2 hypertension (BP ≥140/90 mmHg). According to the ACE inhibitor mechanism document, the typical starting dose of lisinopril is 10mg once daily, with titration up to 40mg daily based on response. For this diabetic patient, ACE inhibitors are particularly beneficial because they provide renoprotective effects beyond blood pressure control. The hypertension management document notes that ACE inhibitors are preferred first-line agents in diabetic patients, reducing albuminuria and slowing diabetic nephropathy progression by dilating the efferent arteriole and reducing intraglomerular pressure.
      Answer: Lisinopril 10mg once daily is the standard starting dose. ACE inhibitors are preferred in diabetic patients due to renoprotective effects, reducing albuminuria and slowing diabetic nephropathy progression.
